Monsanto-Bayer merger now unlikely until 2018

bayer

German drugs and pesticides group Bayer said on Tuesday it was now likely to be early next year before it can complete its $66 billion deal to acquire U.S. group Monsanto, later than previously expected.

The European Commission has been scrutinizing the proposed takeover with a deadline of Jan. 8 but Bayer said in a statement it had asked the regulator for an extension on the investigation to Jan. 22, to which the EU Commission responded by saying it would take a decision shortly.

Among a slew of markets where competition was at risk, the EU Commission at the time named Monsanto’s weed killer glyphosate, or Roundup, which competes with Bayer’s glufosinate; vegetable and canola seeds; and licensing of cotton-seed technology to peers.

More broadly, it said the deal might slow the race to develop new products, and that the European Union would try to prevent Bayer from becoming too dominant in combined offerings of seeds and pesticides with the help of digital farming tools such as connected sensors, software and precision machines.

Bayer, which was making a media presentation on its Crop Science business on Tuesday, also said the division would face volatile global markets for the rest of the year but would slowly return to growth from 2018….

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion and analysis. Read full, original post: Bayer says needs more time for Monsanto deal approval

{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}

Related Articles

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Does glyphosate—the world's most heavily-used herbicide—pose serious harm to humans? Is it carcinogenic? Those issues are of both legal and ...

Most Popular

ChatGPT-Image-Mar-10-2026-01_39_01-PM
Viewpoint—“Miracle molecule” debunked: Why acemannan supplements don’t work
ChatGPT-Image-Jun-25-2026-12_23_17-PM
No, Bill Gates did not secretly engineer ticks to promote veganism
ChatGPT-Image-Jun-30-2026-10_27_31-AM
Viewpoint: Europe clears the way for gene-edited crops — but fear-driven restrictions still slow their full potential
ChatGPT-Image-Jul-1-2026-12_37_08-PM
Viewpoint: Trump poised to politicize all U.S.-supported science research
ChatGPT-Image-Jul-1-2026-03_33_49-PM
‘Alternative’ cancer treatments that could kill you
DtAieAIkCZy-uchn-oqg
Viewpoint: In the science misinformed grifter game plan, the organic-food-is-healthier myth might be the worst.
ChatGPT-Image-Jul-7-2026-03_07_17-PM
Kennedy blocks preventive health care panel that reviews treatments for HIV, diabetes, and cancer from meeting — for fourth time
d a ca e c c beb x
Facts & Fallacies podcast: The 'woke' crusade against anthropology? Dr. Elizabeth Weiss
ChatGPT-Image-Jul-7-2026-12_01_35-PM
Viewpoint: 21 worthless wellness trends inspired by RFK, Jr.’s ill-informed MAHA followers that can harm or even kill you.
ChatGPT-Image-Jun-15-2026-01_04_14-PM
Viewpoint: How politicized science became a political religion 
ChatGPT-Image-Jun-15-2026-03_00_23-PM
World’s first AI-designed vaccine explained

Sorry. No data so far.

glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.